Company Overview

As of July 19, 2010, DOV Pharmaceutical Inc. was acquired by Euthymics Bioscience, Inc. DOV Pharmaceutical, Inc., a biopharmaceutical company, engages in the discovery, in-licensing, and development of novel drug candidates for central nervous system disorders. Its product candidate include DOV 21,947, a triple reuptake inhibitor, which is in Phase II clinical trials for depression, as well as in preclinical studies for obesity; Bicifadine for the treatment of pain or analgesics, which is in Phase II/Phase III(2) clinical trials; DOV diltiazem for the treatment of hypertension and angina is in Phase I/III(3); and DOV 102,677, which is in Phase I(4) for alcohol abuse. The company also involve...

As of July 19, 2010, DOV Pharmaceutical Inc. was acquired by Euthymics Bioscience, Inc. DOV Pharmaceutical, Inc., a biopharmaceutical company, engages in the discovery, in-licensing, and development of novel drug candidates for central nervous system disorders. Its product candidate include DOV 21,947, a triple reuptake inhibitor, which is in Phase II clinical trials for depression, as well as in preclinical studies for obesity; Bicifadine for the treatment of pain or analgesics, which is in Phase II/Phase III(2) clinical trials; DOV diltiazem for the treatment of hypertension and angina is in Phase I/III(3); and DOV 102,677, which is in Phase I(4) for alcohol abuse. The company also involves in the preclinical discovery and development programs, such as DOV 216,419 which is in Pre-IND(5) preclinical trails for depression and pain; and Uptake inhibitors and GABA modulators for various central nervous system disorders. In addition, DOV Pharmaceutical develops Indiplon, a program subject to regulatory review for the treatment of insomnia. It has strategic collaborations and licensing agreements with XTL Biopharmaceuticals, Inc., for bicifadine; Blue Note Pharmaceuticals, Inc., for DOV diltiazem; and Neurocrine Biosciences, Inc., for indiplon, as well as Wyeth Holdings Corporation. The company was founded in 1995 and is headquartered in Somerset, New Jersey.

Key Executives for DOV Pharmaceutical Inc.

Similar Private Companies By Industry

Recent Private Companies Transactions